Pharmacokinetics of ceftazidime in patients with renal insufficiency and in those undergoing hemodialysis. 1985

M Ohkawa, and T Nakashima, and R Shoda, and A Ikeda, and M Orito, and M Sawaki, and T Sugata, and M Shimamura, and S Hirano, and K Okumura

The pharmacokinetics of ceftazidime, a new cephalosporin antibiotic, were studied in 7 healthy volunteers and 32 patients with renal insufficiency after a single 500-mg intravenous injection. The mean plasma half-life during beta-phase was 1.67 h in normal subjects and was prolonged to 15.09 h in hemodialysis patients. There were significant correlations between the elimination rate constant and the creatinine clearance, and between the beta-phase rate constant and the creatinine clearance. The mean urinary recovery during 24 h amounted to 89.6% of the dose in normal subjects and decreased with the lowering of renal function. The plasma levels during hemodialysis were lower than those between hemodialyses.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002442 Ceftazidime Semisynthetic, broad-spectrum antibacterial derived from CEPHALORIDINE and used especially for Pseudomonas and other gram-negative infections in debilitated patients. Ceftazidime Anhydrous,Ceftazidime Pentahydrate,Fortaz,Fortum,GR-20263,LY-139381,Pyridinium, 1-((7-(((2-amino-4-thiazolyl)((1-carboxy-1-methylethoxy)imino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, inner salt, pentahydrate, (6R-(6alpha,7beta(Z)))-,Tazidime,GR 20263,GR20263,LY 139381,LY139381
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses

Related Publications

M Ohkawa, and T Nakashima, and R Shoda, and A Ikeda, and M Orito, and M Sawaki, and T Sugata, and M Shimamura, and S Hirano, and K Okumura
February 1984, Antimicrobial agents and chemotherapy,
M Ohkawa, and T Nakashima, and R Shoda, and A Ikeda, and M Orito, and M Sawaki, and T Sugata, and M Shimamura, and S Hirano, and K Okumura
January 1979, Therapie,
M Ohkawa, and T Nakashima, and R Shoda, and A Ikeda, and M Orito, and M Sawaki, and T Sugata, and M Shimamura, and S Hirano, and K Okumura
October 1983, Antimicrobial agents and chemotherapy,
M Ohkawa, and T Nakashima, and R Shoda, and A Ikeda, and M Orito, and M Sawaki, and T Sugata, and M Shimamura, and S Hirano, and K Okumura
December 1986, Antimicrobial agents and chemotherapy,
M Ohkawa, and T Nakashima, and R Shoda, and A Ikeda, and M Orito, and M Sawaki, and T Sugata, and M Shimamura, and S Hirano, and K Okumura
November 1984, Antimicrobial agents and chemotherapy,
M Ohkawa, and T Nakashima, and R Shoda, and A Ikeda, and M Orito, and M Sawaki, and T Sugata, and M Shimamura, and S Hirano, and K Okumura
June 1991, Antimicrobial agents and chemotherapy,
M Ohkawa, and T Nakashima, and R Shoda, and A Ikeda, and M Orito, and M Sawaki, and T Sugata, and M Shimamura, and S Hirano, and K Okumura
January 2009, International journal of clinical pharmacology and therapeutics,
M Ohkawa, and T Nakashima, and R Shoda, and A Ikeda, and M Orito, and M Sawaki, and T Sugata, and M Shimamura, and S Hirano, and K Okumura
December 1994, The American journal of cardiology,
M Ohkawa, and T Nakashima, and R Shoda, and A Ikeda, and M Orito, and M Sawaki, and T Sugata, and M Shimamura, and S Hirano, and K Okumura
October 2001, Cornea,
M Ohkawa, and T Nakashima, and R Shoda, and A Ikeda, and M Orito, and M Sawaki, and T Sugata, and M Shimamura, and S Hirano, and K Okumura
March 1995, Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic],
Copied contents to your clipboard!